| Medical Imaging to Re-evaluate Elacestrant Clinical Usage (NCT07753954) | Jules Bordet Institute | 2026-09-13 |
| Randomized Clinical Investigation of Photobiomodulation (PBM) for the Management of Early Peripheral Neuropathy Related to Medical Oncologic Therapy (NCT07681921) | Jules Bordet Institute | 2026-09-01 |
| SCALp Cooling for pReventing aLopecia With nEw anTibody-drug Conjugates (NCT07474558) | Jules Bordet Institute | 2026-09-01 |
| HER2 Molecular Imaging With 89Zr-trastuzumab PET/CT as a Predictive Biomarker for Antibody-drug Conjugate Sequencing in Patients With Advanced HER2-positive Breast Cancer (NCT06595563) | Jules Bordet Institute | 2026-06-30 |
| Holistic Evaluation of Approaches to Long-term Health & Survivorship (NCT07745205) | Jules Bordet Institute | 2026-06-08 |
| Immune Fitness in Older Patients With Relapsed and Refractory Multiple Myeloma (NCT07674498) | Jules Bordet Institute | 2026-06-03 |
| Pregnancy Outcomes After Breast Cancer in Young Women With Germline Pathogenic Variants in Genes Other Than BRCA (NCT07591532) | Jules Bordet Institute | 2026-06-01 |
| Integrating Peritoneal Histological Growth Patterns Into Preoperative Decision-Making for Colorectal Peritoneal Metastses (NCT07474025) | Jules Bordet Institute | 2026-03-01 |
| Testosterone Supplementation in Patients in Best Supportive Care: Impact on Quality of Life (NCT07143279) | Jules Bordet Institute | 2026-02-11 |
| LUtetium-177 DOsimetry as a Predictive Biomarker of Response in Metastatic Prostate Cancer Patients Treated With PSMA Radioligand THerapy. (NCT07370597) | Jules Bordet Institute | 2026-02-01 |
| Prophylactic Intervention for Dysgeusia in Head and Neck Cancer Patients Following Radio(Chemo)Therapy (NCT07431346) | Jules Bordet Institute | 2026-02-01 |
| Ventral Hernias Following Cytoreductive Surgery : Incidence, Risk Factors and Surgical Management. (NCT07451483) | Jules Bordet Institute | 2026-01-20 |
| Management of Acute Complicated Diverticulitis: An Assessment of Current Practices (NCT07601958) | Jules Bordet Institute | 2025-12-01 |
| Stereotactic Radiotherapy for Oligoprogressive ER+/HER- Metastatic Breast Cancer, a Prospective Phase 2 Study (Oligopro-Breast) (NCT06925984) | Jules Bordet Institute | 2025-10-30 |
| Molecular Imaging of Cancer-associated Fibroblasts in Glioblastoma: a FAPI PET/MR Study. (NCT07119294) | Jules Bordet Institute | 2025-08-01 |
| The Role of the Imaging FAPI PET/CT in Exploring the Microenvironment of Colorectal Cancer Liver Metastases (NCT07109440) | Jules Bordet Institute | 2025-05-09 |
| Evaluation of the RESTART Survival Programme (NCT06283511) | Jules Bordet Institute | 2025-03-01 |
| Salvage Stereotactic Body Radiotherapy of the Prostate Bed for Biochemical Recurrence After Radical Prostatectomy. (NCT06523634) | Jules Bordet Institute | 2024-12-10 |
| The Added-value of PSMA PET in Detecting Clinically Significant Prostate Cancer Lesions in Patients Undergoing MRI-targeted Biopsy. (PANDORA) (NCT06867588) | Jules Bordet Institute | 2024-10-17 |
| A Phase I Study to Assess the Tolerability of 225Ac-DOTATATE in Patients With Refractory and Relapsing Multiple Myeloma Expressing Somatostatin Receptors (NCT06411301) | Jules Bordet Institute | 2024-10-01 |
| Assessment of DW-MRI Measures : Reproducibility and Repeatability in Pelvic Imaging on MR-Linac With Healthy Volunteers (NCT06458725) | Jules Bordet Institute | 2024-06-13 |
| ICG-fluorescence Imaging for Intraoperative Breast Cancer Margins Evaluation: a Dose-timing Study (NCT06227338) | Jules Bordet Institute | 2024-02-12 |
| A Study of On-treatment ctDNA Changes in Chemo-refractory Colorectal Cancer Patients (NCT05487248) | Jules Bordet Institute | 2023-10-12 |
| PROstate CAncer Radiotherapy - Bowel Quality of Life (PROCAR-BQ) (NCT05880446) | Jules Bordet Institute | 2023-10-06 |
| To Explore the Benefits of the MonaLisa Touch® System in Gynaecological Cancer Patients Treated by (Chemo)-RT (NCT05891470) | Jules Bordet Institute | 2023-09-01 |
| Ga68-FAPI-46 PET/CT for Preoperative Assessment of Peritoneal Carcinomatosis (NCT06061874) | Jules Bordet Institute | 2023-05-30 |
| Immunological Variables Associated to ICI Toxicity in Cancer Patients (NCT05429866) | Jules Bordet Institute | 2022-09-01 |
| Multidisciplinary Approach to Fatigue (NCT05502224) | Jules Bordet Institute | 2022-08-19 |
| Inferior Epigastric Lymp Node (IELN) Basin as a Possible Systemic Metastatic Pathway of Ovarian Peritoneal Metastases (NCT06237582) | Jules Bordet Institute | 2022-06-16 |
| PSMA-PET/CT to Assess the Expression of Specific Membrane Antigen (PSMA) in Patients With Progressive Triple-negative Breast Cancer. (NCT06059469) | Jules Bordet Institute | 2022-05-30 |
| Inferior Epigastric Lymph Node in Colorectal Carcinosis (NCT04966715) | Jules Bordet Institute | 2022-02-03 |
| De-escalation Adjuvant Chemo in HER2+/ER-/node-neg Early BC Patients Who Achieved PCR After Neoadjuvant Chemo & Dual HER2 Blockade (NCT04675827) | Jules Bordet Institute | 2022-01-17 |
| COVID-19: Immune Response in Patients With Cancer Undergoing mRNA Vaccination Against SARS-CoV-2 (NCT05075538) | Jules Bordet Institute | 2021-12-01 |
| Evaluation of Neratinib for Treatment and Prevention of Subsequent CNS Event(s) in Patients With Brain Metastasis of Advanced HER2 Positive Breast Cancer (NCT04856475) | Jules Bordet Institute | 2021-11-24 |
| Assessment of (Chemo)RT-related Dysphagia in HNC Patients Based on Cough-related Acoustic Features (NCT05865756) | Jules Bordet Institute | 2021-04-01 |
| Neoadjuvant Regorafenib in Combination With Nivolumab and Short-course Radiotherapy in Stage II-III Rectal Cancer (NCT04503694) | Jules Bordet Institute | 2021-03-25 |
| Micro-wave Ablation Under Organ-based Tracking in Patients With Prostate Cancer - FOSTINE (NCT04831905) | Jules Bordet Institute | 2021-03-01 |
| Neoadjuvant Study of Targeting ROS1 in Combination With Endocrine Therapy in Invasive Lobular Carcinoma of the Breast (ROSALINE) (NCT04551495) | Jules Bordet Institute | 2021-01-14 |
| Efficacy of the Mepitel® Film on the Prevention of Radiodermatitis in the Inguinal Fold. (NCT04617730) | Jules Bordet Institute | 2021-01-01 |
| A Mixed Method to Study Adherence to Oral Anticancer Medications in a Multilingual and Multicultural Setting (NCT04613765) | Jules Bordet Institute | 2020-12-01 |
| Prospective Pilot Study Evaluating Dental Side Effects of Radiotherapy on Subjects Treated for Head and Neck Cancer (NCT04452032) | Jules Bordet Institute | 2020-11-17 |
| A Brain Metastases Research Platform to Tackle the Challenge of CNS Metastases in Solid Tumours (NCT04109131) | Jules Bordet Institute | 2020-07-01 |
| Somatostatin Receptors Imaging in Relapsing and Refractory Multiple Myeloma Patients (NCT04379817) | Jules Bordet Institute | 2020-02-25 |
| Assessment of Swallowing Function and Quality of Life in Oropharyngeal Cancer Patients Treated by Chemo-radiotherapy (NCT04019548) | Jules Bordet Institute | 2019-12-16 |
| Neo-adjuvant Chemotherapy Combined With Stereotactic Body Radiotherapy to the Primary Tumour +/- Durvalumab, +/- Oleclumab in Luminal B Breast Cancer: (NCT03875573) | Jules Bordet Institute | 2019-11-06 |
| Paclitaxel + Carboplatin + Durvalumab With or Without Oleclumab for Previously Untreated Locally Recurrent Inoperable or Metastatic TNBC (NCT03616886) | Jules Bordet Institute | 2018-12-28 |
| Multiorgan Metabolic Imaging Response Assessment of Abemaciclib (NCT03339843) | Jules Bordet Institute | 2018-12-19 |
| Avelumab as Neoadjuvant Therapy in Subjects With Urothelial Muscle Invasive Bladder Cancers (AURA Trial) (NCT03674424) | Jules Bordet Institute | 2018-06-01 |